1. Pink Sheet

Califf: Decades Of Follow-Up Necessary For Gene Therapy

 
• By Sarah Karlin-Smith

FDA Commissioner Califf acknowledges that regulatory pathways for gene therapies are still being developed and that many factors outside of the modality impact agency requirements as he emphasized the need for long-term follow up due to the unknowns of gene modification.

editing DNA
Unknowns about gene therapy effects won’t preclude fast approvals but will demand lengthy follow up, Commissioner Califf said • Source: Shutterstock

Long periods of follow-up may be necessary for gene therapies, particularly if and when the US Food and Drug Administration is willing to grant a company an accelerated approval for such a treatment, FDA Commissioner Robert Califf said.

At the J.P

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies